Raymond James Financial
KPRX icon

Raymond James Financial’s Kiora Pharmaceuticals KPRX Stock Holding History

Raymond James Financial’s Portfolio KPRX Stock Details KPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2
Closed -$6 – 5891
2025
Q2 		$6 Buy
+2
New +$6 ﹤0.01% 6952

Other funds holding KPRX

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Raymond James Financial's KPRX Position: Q3 2025 in Review

Raymond James Financial sold out of Kiora Pharmaceuticals (KPRX) in Q3 2025, closing a stake of 2 shares — an estimated $6 sold.

Raymond James Financial first reported a position in KPRX in Q2 2025 and held it in 1 quarter. The position peaked at $6 in Q2 2025. 17 funds tracked by Wall St. Rank hold KPRX as of Q3 2025.

  • Raymond James Financial reported no remaining Kiora Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 2 Kiora Pharmaceuticals shares in Q3 2025, an estimated $6.
  • Raymond James Financial first reported a position in Kiora Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Kiora Pharmaceuticals position peaked at $6 in Q2 2025.
  • 17 funds tracked by Wall St. Rank held Kiora Pharmaceuticals as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.